Desferrioxamine Mesylate (DBL)™
Active ingredients: Desferrioxamine
Consumer medicine information
Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
Chronic Iron Overload. Desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. Long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. The drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. Desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. Acute iron poisoning: Desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.
Source: ARTG
Storage conditions
- Shelf lifetime is 2 Years
- Store below 25 degrees Celsius
- Protect from Light
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Injection, powder for
- Intravenous
- White to cream powder or lyophilised plug.
Source: ARTG
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
- 1 x 50mL vial
Source: ARTG
Is this medicine subsidised?
This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 November 2026, under PBS item codes 6270B (Opens in new tab) and 5661Y (Opens in new tab). Ask your pharmacist or doctor about your eligibility
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Desferrioxamine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 4 November 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 4 November 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 November 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice
